Drug Trial Radar · NCT04680949
suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19
Last checked: Nov 20, 2026Latest source record: Sep 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
606
Actual
Start
Dec 23, 2020
Primary completion
Mar 31, 2021
Study completion Feb 6, 2022
Sponsor
- Lead sponsor
- Hellenic Institute for the Study of SepsisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 over 28 days as measured by the ordinal scale of the 11-point World Health Organization (WHO) clinical progression scale (CPS).
Conditions
- Covid19
Interventions
AnakinraDrug
Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days
PlaceboDrug
Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of the distribution of frequencies of each score of a 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatmentTime frame: 28 days
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Greece
10th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
Athens, Greece
1st Department of Internal Medicine, AMALIA FLEMING Prefecture General Hospital of Melissia
Athens, Greece
1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.
Athens, Greece
1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO
Athens, Greece
1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION
Athens, Greece
1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO
Athens, Greece
1st University Department of Internal Medicine, General Hospital of Athens LAIKO
Athens, Greece
1st University Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
Athens, Greece
2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO
Athens, Greece
2nd Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
Athens, Greece
2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens
Athens, Greece
3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S.
Athens, Greece
3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA
Athens, Greece
4th Department of Internal Medicine, ATTIKON University General Hospital
Athens, Greece
4th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
Athens, Greece
5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens
Athens, Greece
COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING
Athens, Greece
Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens
Athens, Greece
Department of COVID-19, Evangelismos General Hospital
Athens, Greece
Department of Internal Medicine, General Hospital of Athens Elpis
Athens, Greece
• 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS
Athens, Greece
• Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA
Athens, Greece
Department of Pulmonary Medicine, General Hospital of Kerkyra
Corfu, Greece
1st Department of Internal Medicine, General University Hospital of Ioannina
Ioannina, Greece
Department of Internal Medicine, University General Hospital of Larissa,
Larissa, Greece
Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA
Pátrai, Greece
2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO
Piraeus, Greece
1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki
Thessaloniki, Greece
1st Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki
Thessaloniki, Greece
2nd Department of Propedeutic Medicine, Ippokrateion University General Hospital of Thessaloniki
Thessaloniki, Greece
3rd University Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki
Thessaloniki, Greece
Dipartimento di Medicina Dipartimento di Malattie Infettive, ASST Spedali civili
Brescia, Italy
Unità Operativa Clinica Malattie Infettive, Ospedale Policlinico San Martino
Genova, Italy
Dipartimento di Medicina Interna, Istituto Clinico Humanitas
Milan, Italy
Medicina Interna, Reumatologia, Immunologia, IRCCS San Raffaele
Milan, Italy
Dipartimento di Malattie Infettive e Tropicali e Microbiologia, IRCCS Ospedale Sacro Cuore Don Calabria
Negrar, Italy
Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose, IRCCS Lazzaro Spallanzani
Roma, Italy
Dipartimento Scienze di laboratorio e infettivologiche, Policlinico Universitario Agostino Gemelli
Roma, Italy
Dipartimento di Malattie infettive e tropicali-Università dell'Insubria, ASST dei Sette Laghi
Varese, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.